Cargando…

CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis

CUGBP Elav‐like family member 2(CELF2) plays crucial roles in the development and activation of T cell. However, the impacts of CELF2 on tumour‐infiltrating immune cells (TIICs) and clinical outcomes of tumours remain unclear. In this study, we found that elevated CELF2 expression was markedly corre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Libo, Liu, Zaoqu, Liu, Long, Guo, Chunguang, Jiao, Dechao, Li, Lifeng, Zhao, Jie, Han, Xinwei, Sun, Yuling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335674/
https://www.ncbi.nlm.nih.gov/pubmed/34288370
http://dx.doi.org/10.1111/jcmm.16791
_version_ 1783733160966619136
author Wang, Libo
Liu, Zaoqu
Liu, Long
Guo, Chunguang
Jiao, Dechao
Li, Lifeng
Zhao, Jie
Han, Xinwei
Sun, Yuling
author_facet Wang, Libo
Liu, Zaoqu
Liu, Long
Guo, Chunguang
Jiao, Dechao
Li, Lifeng
Zhao, Jie
Han, Xinwei
Sun, Yuling
author_sort Wang, Libo
collection PubMed
description CUGBP Elav‐like family member 2(CELF2) plays crucial roles in the development and activation of T cell. However, the impacts of CELF2 on tumour‐infiltrating immune cells (TIICs) and clinical outcomes of tumours remain unclear. In this study, we found that elevated CELF2 expression was markedly correlated with prolonged survival in multiple tumours, particularly in breast and lung cancers. Notably, CELF2 only impacted the prognosis of triple‐negative breast cancer (TNBC) with lymph node metastasis. Further investigation showed CELF2 expression was positively correlated with the infiltration abundance of dendritic cells (DCs), CD8+ T cells and neutrophils in breast invasive carcinoma (BRCA) and DCs in lung squamous cell carcinoma (LUSC). CELF2 also had strong correlations with markers of diverse TIICs such as T cells, tumour‐associated macrophages and DCs in BRCA and LUSC. Importantly, CELF2 was significantly associated with plenty of immune checkpoint molecules (ICMs) and outperformed five prevalent biomarkers including PD‐1, PD‐L1, CTLA‐4, CD8 and tumour mutation burden in predicting immunotherapeutic responses. Immunohistochemistry also revealed lower protein levels of CELF2 in TNBC and LUSC compared to normal tissues, and patients with high expression showed significantly prolonged prognosis. In conclusion, we demonstrated that increased CELF2 expression was closely related to better prognosis and superior TIIC infiltration and ICM expression, particularly in BRCA and LUSC. CELF2 also performed well in evaluating the immunotherapeutic efficacy, suggesting CELF2 might be a promising biomarker.
format Online
Article
Text
id pubmed-8335674
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83356742021-08-09 CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis Wang, Libo Liu, Zaoqu Liu, Long Guo, Chunguang Jiao, Dechao Li, Lifeng Zhao, Jie Han, Xinwei Sun, Yuling J Cell Mol Med Original Articles CUGBP Elav‐like family member 2(CELF2) plays crucial roles in the development and activation of T cell. However, the impacts of CELF2 on tumour‐infiltrating immune cells (TIICs) and clinical outcomes of tumours remain unclear. In this study, we found that elevated CELF2 expression was markedly correlated with prolonged survival in multiple tumours, particularly in breast and lung cancers. Notably, CELF2 only impacted the prognosis of triple‐negative breast cancer (TNBC) with lymph node metastasis. Further investigation showed CELF2 expression was positively correlated with the infiltration abundance of dendritic cells (DCs), CD8+ T cells and neutrophils in breast invasive carcinoma (BRCA) and DCs in lung squamous cell carcinoma (LUSC). CELF2 also had strong correlations with markers of diverse TIICs such as T cells, tumour‐associated macrophages and DCs in BRCA and LUSC. Importantly, CELF2 was significantly associated with plenty of immune checkpoint molecules (ICMs) and outperformed five prevalent biomarkers including PD‐1, PD‐L1, CTLA‐4, CD8 and tumour mutation burden in predicting immunotherapeutic responses. Immunohistochemistry also revealed lower protein levels of CELF2 in TNBC and LUSC compared to normal tissues, and patients with high expression showed significantly prolonged prognosis. In conclusion, we demonstrated that increased CELF2 expression was closely related to better prognosis and superior TIIC infiltration and ICM expression, particularly in BRCA and LUSC. CELF2 also performed well in evaluating the immunotherapeutic efficacy, suggesting CELF2 might be a promising biomarker. John Wiley and Sons Inc. 2021-07-19 2021-08 /pmc/articles/PMC8335674/ /pubmed/34288370 http://dx.doi.org/10.1111/jcmm.16791 Text en © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Wang, Libo
Liu, Zaoqu
Liu, Long
Guo, Chunguang
Jiao, Dechao
Li, Lifeng
Zhao, Jie
Han, Xinwei
Sun, Yuling
CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis
title CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis
title_full CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis
title_fullStr CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis
title_full_unstemmed CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis
title_short CELF2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: A pan‐cancer analysis
title_sort celf2 is a candidate prognostic and immunotherapy biomarker in triple‐negative breast cancer and lung squamous cell carcinoma: a pan‐cancer analysis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335674/
https://www.ncbi.nlm.nih.gov/pubmed/34288370
http://dx.doi.org/10.1111/jcmm.16791
work_keys_str_mv AT wanglibo celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis
AT liuzaoqu celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis
AT liulong celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis
AT guochunguang celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis
AT jiaodechao celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis
AT lilifeng celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis
AT zhaojie celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis
AT hanxinwei celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis
AT sunyuling celf2isacandidateprognosticandimmunotherapybiomarkerintriplenegativebreastcancerandlungsquamouscellcarcinomaapancanceranalysis